INTRODUCTION: JNK, Jun N-terminal Kinase is a protein kinase which is stress-activated, and it can be developed by means of different inflammatory cytokines, various bacterial endotoxins, Ultraviolet radiations, osmotic shock waves and hypoxia. SP600125 is an anthrapyrazolone series reversible ATP-competitive inhibitor, which can significantly inhibit the JNK 1, 2 and 3. This molecule possesses more than 20 folds increased selectivity as compared to the other molecules and enzymes that have been tested for the same purpose. SP600125 AS AN INHIBITOR: SP600125 is an inhibitor or C-Jun N-terminal, which specifically inhibit this molecule and has been considered as a ligand. It blocks the aryl hydrocarbon receptor called as AhR [1]. In actual SP600125 is not an antagonist, rather it is the partial agonist of human AhR. This molecule significantly produces the CYP1A1 and CYP1A2 mRNAs inside the liver cells. In addition to that it also develops CYP1A1 mRNA in the second type of liver cells called as HepG2 [2]. SP600125 WHAT IT DOES? The action of SP600125 is dose dependent, and accordingly it inhibits CYP1A1 and CYP1A2 genes by means of prototype AhR ligand in human liver cells called as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In addition to that, SP600125 exhibits consistent behavior like a partial agonist in HepG2 cells. It acts like a temporary transfected along with the reporter plasmid possessing two inverted repetitions of the dioxin elements. In the absence of this responsive dioxin element, it can also be presented with a plasmid that contains 50'anking region of human CYP1A1 gene. SP600125 MECHANISM OF ACTION: SP600125 can bring CYP1A1 and A2 mRNAs in the human liver cells. However, the concentration of induction does not co-relate to the full activation of AhR. SP600125 can inhibit CYP1A1 and A2 mRNA induction in liver cells by means of AhR agonists, called as TCDD. Same type of effect of SP600125 is observed in the other variety of liver cells called as HepG2 cells in mRNA expression having AhR-mediated CYP1A1. SP600125 possesses specific behavior as a partial agonist. These behaviors can be evident in the gene reporter assays which are performed in HepG2 cells. Since AhR blocker resveratrol can diminish the production of CYP1A genes by the help of SP600125 in the liver cells and HepG2 cells, hence the impacts of SP600125 can take place by means of AhR. Various experiments and research studies have demonstrated that SP600125 can inhibit the cell proliferation in CD4 cells [3]. However, it does not destroy these cells. This is the reason why SP600125 is considered as possessing the cystostatic effect on the T cell proliferation. CONCLUSION: In conclusion, SP600125 is a little molecule that can inhibit the JNK. The research studies have shown that JNK performs significant role in the transcription factor activation, apoptotic progression, mRNA stabilization and cellular proliferation, etc. SP600125 could be useful in situations, where JNK inhibition can perform a central role in the prevention of certain diseases inside the human body, like infarction, stroke, chronic neuronal cell death, ischemia perfusion injury, etc. REFERENCES: 1. Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners Jr JJ. The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab Dispos 2003;31(11):127982. 2. Radim Vrzal, Pavla Henklova, Petra Jancova, Eva Anzenbacherova, Patrick Maurel, Lucie Svecova et al. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2genes in primary human hepatocytes Zdenek Dvorak. b i o c h e m i c a l p h a r m a c o l o g y 7 5 ( 2 0 0 8 ) 5 8 0 5 8 8. 3. Brydon L. Bennett, Dennis T. Sasaki, Brion W. Murray, Eoin C. O’Leary, Steve T. Sakata, Weiming Xu et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. PNAS November 20, 2001 vol. 98 no. 24 13681-13686.
Please Rate this Article 5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
